Invasive fungal infections are a significant cause of morbidity and mortality in immunocompromised patients and voriconazole is often prescribed because of its potent activity. Treatment success of voriconazole therapy is highly dependent on maintaining therapeutic concentrations which is challenging due to the high inter- and intra-patient variability in drug exposure. The complex kinetics of voriconazole renders current manufacturersâ dosing guidelines ineffective. The variability in drug exposure observed in clinical settings has been linked to genetic polymorphisms in the cytochrome P450 2C19 gene, which encodes for the enzyme primarily responsible for voriconazole metabolism. Therapeutic drug monitoring has been found to increase eff...
www.theannals.com Voriconazole is an antifungal agent approved for use ininvasive Aspergillus infect...
Objectives: Voriconazole exhibits highly variable, non-linear pharmacokinetics and is associated wit...
BACKGROUND: Voriconazole is the therapy of choice for aspergillosis and a new treatment option for c...
Invasive fungal infections are a significant cause of morbidity and mortality in immunocompromised p...
The aim of this study was to determine an optimum voriconazole target concentration, to study the in...
Artículo de publicación ISIVoriconazole (VCZ) use is limited by its narrow therapeutic range and sig...
Many factors have been described to contribute to voriconazole (VCZ) interpatient variability in pla...
(See the editorial commentary by Lewis on pages 212–4) Background. Voriconazole is the therapy of ch...
Highly variable and non-linear pharmacokinetics of voriconazole are mainly caused by CYP2C19 polymor...
Genetic polymorphisms of cytochrome P450 enzymes, especially CYP2C19, could influence voriconazole p...
Invasive fungal infections (IFIs) are the most frequent cause of morbidity and mortality in immunoco...
Objective: This study aimed to determine the portion of Iranian patients who attain therapeutic seru...
Voriconazole is among the first-line antifungal drugs to treat invasive fungal infections in childre...
Contains fulltext : 70639.pdf (publisher's version ) (Closed access)Voriconazole i...
Voriconazole is a first-line antifungal agent. Therapeutic drug monitoring is a standard of care. Th...
www.theannals.com Voriconazole is an antifungal agent approved for use ininvasive Aspergillus infect...
Objectives: Voriconazole exhibits highly variable, non-linear pharmacokinetics and is associated wit...
BACKGROUND: Voriconazole is the therapy of choice for aspergillosis and a new treatment option for c...
Invasive fungal infections are a significant cause of morbidity and mortality in immunocompromised p...
The aim of this study was to determine an optimum voriconazole target concentration, to study the in...
Artículo de publicación ISIVoriconazole (VCZ) use is limited by its narrow therapeutic range and sig...
Many factors have been described to contribute to voriconazole (VCZ) interpatient variability in pla...
(See the editorial commentary by Lewis on pages 212–4) Background. Voriconazole is the therapy of ch...
Highly variable and non-linear pharmacokinetics of voriconazole are mainly caused by CYP2C19 polymor...
Genetic polymorphisms of cytochrome P450 enzymes, especially CYP2C19, could influence voriconazole p...
Invasive fungal infections (IFIs) are the most frequent cause of morbidity and mortality in immunoco...
Objective: This study aimed to determine the portion of Iranian patients who attain therapeutic seru...
Voriconazole is among the first-line antifungal drugs to treat invasive fungal infections in childre...
Contains fulltext : 70639.pdf (publisher's version ) (Closed access)Voriconazole i...
Voriconazole is a first-line antifungal agent. Therapeutic drug monitoring is a standard of care. Th...
www.theannals.com Voriconazole is an antifungal agent approved for use ininvasive Aspergillus infect...
Objectives: Voriconazole exhibits highly variable, non-linear pharmacokinetics and is associated wit...
BACKGROUND: Voriconazole is the therapy of choice for aspergillosis and a new treatment option for c...